At the same time, cell therapy with rCD8+ T-cells of the spleen has an inhibitory effect on lung cancer cells and CSCs expressing Sox2 and markers Axl, CD117, EGF, PD-L1 and PD-1. Here, AXL is linked to lung cancer.